Penpulimab

派安普利单抗

Report date: 2025/12/29 09:31:48

Base Information

Drug NamePenpulimab
Drug Alias Name安尼可ANNIKOAK-105
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody human
Mechanisms of ActionProgrammed cell death protein 1 blockers
TargetsProgrammed cell death protein 1
Therapy Area/IndicationsSolid tumoursMicrosatellite instability-high cancerUrologic Neoplasms +[15] 
Global Approved IndicationsNasopharyngeal CarcinomaHodgkin Disease
Approved Indications in ChinaHodgkin Disease
Original Approved Country/TerritoryMainland China
Original Approved Date2021/08/03
Country/TerritoryCanadaUnited StatesAustralia +[5] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesZhongshan Akeso Biopharma Co Ltd
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesAkeso Pharmaceuticals IncSpecialised Therapeutics Asia Pte LtdZhongshan Akeso Biopharma Co Ltd +[6] 
Inactive CompaniesAkeso Tiancheng IncAkesobio Australia Pty LtdSun Yat-Sen University
Active IndicationsSolid tumoursSmall Cell Lung CarcinomaCarcinoma, Non-Small-Cell Lung +[7] 
Inactive IndicationsMicrosatellite instability-high cancerUrologic NeoplasmsThoracic Neoplasms +[8] 

Other Information

ATC CodeL01XC
Related LinksWikipediaDrugBankKEGG